The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 1, 2007, Pages 32-40

  Avogaro, Angelo ^a   Guida, Pietro ^a   Giorda, Carlo ^a   Mannucci, Edoardo ^a   Medea, Gerardo ^a   Comaschi, Marco ^a   Velussi, Mario ^a   Armienti, Guglielmo ^a   Zucchetti, Roberta ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cholesterol; Diabetes mellitus; Prescriptions; Statins; Vascular complications

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

ANGINA;

EID: 33845431270     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2005.12.001     Document Type: Article

References (38)

1. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. JAMA 251 (1984) 351-364
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
4. Sacks F.M., Pfeffer M.A., Moyé L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on cholesterol events. N Engl J Med 335 (1996) 1001-1009
5. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
6. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
7. Herman W.H., Alexander C.M., Cook J.R., Boccuzzi S.J., Musliner T.A., Pedersen T.R., et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 22 (1999) 1771-1778
8. Collins R., Armitage J., Parish S., Sleight P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
9. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
10. Collaborative Group of the Primary Prevention Project (PPP). Low dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357 (2001) 89-95
11. National Institute for Clinical Excellence. Management of type 2 diabetes: management of blood pressure and blood lipids (2002), National Institute for Clinical Excellence, London
12. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
13. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-572
14. DAI Study Group. The prevalence of coronary heart disease in type 2 diabetic patients in Italy: the DAI study. Diabet Med 21 (2004) 738-745
15. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
16. Morey S.S. American Heart Association issues guidelines on imaging in transient ischemic attacks and stroke. Am Fam Physician 57 (1998) 1685-1686
17. Sacks D., Bakal C.W., Beatty P.T., Becker G.J., Cardella J.F., Raabe R.D., et al. Position statement on the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: a consensus statement developed by the standards division of the society of cardiovascular & interventional radiology. J Vasc Interv Radiol 13 (2002) 353
18. Hakim R.M., and Lazarus J.M. Initiation of dialysis. J Am Soc Nephrol 6 (1995) 1319-1328
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
20. Filardo G., Maggioni A.P., Mura G., Valagussa F., Valagussa L., Schweiger C., et al. The consequences of under-use of coronary revascularization; results of a cohort study in Northern Italy. Eur Heart J 22 (2001) 654-662
21. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 24 (2004) e149-e161
22. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
23. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European action on secondary prevention through intervention to reduce events. Eur Heart J 18 (1997) 1569-1582 Erratum in: Eur Heart J 1998;19:356-7
24. Giorda C., Maggini M., Spila S., Turco S., Raschetti R., and the DAI Study Group. Secondary prevention for coronary artery desease in high risk diabetic patients. Nutr Metab Cardiovasc Dis 13 (2003) 238-243
25. Sukhija R., Aronow W.S., Yalamanchili K., Sinha N., and Babu S. Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. Am J Cardiol 94 (2004) 1358-1359
26. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 17 (2003) 265-285
27. Pontrelli L., Parris W., Adeli K., and Cheung R.C. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 51 (2002) 334-342
28. Winkler K., Abletshauser C., Hoffmann M.M., Friedrich I., Baumstark M.W., Wieland H., et al. Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 87 (2002) 5485-5490
29. Sbarouni E., Kyriakides Z.S., and Kremastinos D. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 32 (1998) 1244-1250
30. Vijan S., Hayward R.A., and American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140 (2004) 650-658
31. Auer J., Berent R., Weber T., and Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 9 (2002) 1831-1850
32. Yee A., Majumdar S.R., Simpson S.H., McAlister F.A., Tsuyuki R.T., and Johnson J.A. Statin use in type 2 diabetes mellitus is associated with a delay in starting insulin. Diabet Med 21 (2004) 962-967
33. Jick S.S., and Bradbury B.D. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 58 (2004) 303-309
34. Klein B.E., Moss S.E., Klein R., and Surawicz T.S. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98 (1991) 1261-1265
35. Wong T.Y., Klein R., Sharrett A.R., Duncan B.B., Couper D.J., Tielsch J.M., et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The atherosclerosis risk in communities study. JAMA 287 (2002) 1153-1159
36. Chew E.Y., Klein M.L., Ferris III F.L., Remaley N.A., Murphy R.P., Chantry K., et al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol 114 (1996) 1079-1084
37. Ferris III F.L., Chew E.Y., and Hoogwerf B.J. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care 19 (1996) 1291-1293
38. Gordon B., Chang S., Kavanagh M., Berrocal M., Yannuzzi L., Robertson C., et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112 (1991) 385-391